DarioHealth Launches Sales of Dario™ Blood Glucose Monitoring System on Amazon Prime

 

Expansion onto Top eCommerce Retailer Platform Expands Accessibility of DarioHealth Products

NEW YORK and CAESAREA, Israel, Feb. 20, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today the launch and first sales of its Dario™ Blood Glucose Monitoring System on Amazon.

DarioHealth is committed to offering people with diabetes more access to its product to help them manage the disease. Distribution on Amazon strengthens DarioHealth's online retail presence, as it provides its users and potential clients with additional purchasing and shipping options, including shipping via Amazon Prime, as all fulfillment is being managed by Amazon. With over 300 million users, Amazon is one of the largest online retailers.

Erez Raphael, Chairman and CEO of DarioHealth, commented, "At DarioHealth, we continuously look for opportunities to enhance our customer experience. By launching on Amazon, we are able to gain brand visibility, awareness, and trust, as Amazon is one of the preeminent sites for online shopping. Our accurate, all-in-one blood glucose monitoring system is now available to order on their purchasing platform, which should appeal to Amazon Prime customers. DarioHealth's game plan for being on Amazon is to reach thousands of more users via the world's largest eCommerce retailer platform."

In order to use the Dario Blood Glucose Monitoring System, users must download the Dario Smart Diabetes Management app, which is available in the App Store and Google Play Store. With the glucose meter measurements, the app can record and track blood glucose levels. In addition, the app can record carb intake, insulin medication, physical activity, and comes with a weight log that lets users track their weight over time.

For more information about DarioHealth on Amazon, please visit: https://www.amazon.com/dp/B0796CZQ6R

About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease treatment, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes the expected benefits of its product's availability on Amazon, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
+1-914-775-5548

DarioHealth Public Relations Contact:
Terese Kelly
Rosica PR
terese@rosica.com
+1-201-843-5600

DarioHealth Investor Relations Contact:
Westwicke Partners
Dario@Westwicke.com
+1-443-213-0500

 

Cision View original content:http://www.prnewswire.com/news-releases/dariohealth-launches-sales-of-dario-blood-glucose-monitoring-system-on-amazon-prime-300601010.html

SOURCE DarioHealth Corp.



RELATED LINKS
http://www.dariohealth.com/

 

Get content for your website

Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Start today.

 

 
 

Contact PR Newswire

Send us an email at info@prnewswire.co.il or call us at +972-77-2005042

 

 
 

Become a PR Newswire client

Send us an email at info@prnewswire.co.il or call us at +972-77-2005042

 

 
  1. Products & Services
  2. News Releases
  3. Contact Us